The Dividend.com blog has it thus:
. . . .Barclays Capital. . . . said it cut its 2009 and 2010 EPS estimates to $3.22 from $3.27 and to $3.40 from $3.41, respectively. . . . [But Barclays] reiterated its “Overweight” rating on Merck, and boosted its price target on the stock to $34 from a prior $31. Merck shares had closed at $33.21 on Friday. . . .
I guess Barclays expects Merck to post a slightly less-robust third quarter 2009, this Thursday -- at least at the EPS line. We'll live blog it all -- both the Schering-Plough and Merck earnings conference-calls, on that morning, so stay tuned right here.
No comments:
Post a Comment